Breaking News, Collaborations & Alliances

Piramal, Bolt Enter Drug Development Deal

For immune-stimulating antibody conjugates and sterile fill-finish.

By: Contract Pharma

Contract Pharma Staff

Piramal Pharma Solutions, a contract development and manufacturing organization (CDMO), said it is providing Bolt Biotherapeutics with the supply of both the BDC-1001 ISAC drug substance and the drug product for Bolt’s ongoing Phase 1/2 clinical study in cancer patients.   The Piramal Pharma Solutions (PPS) team is applying its integrated drug development model to Bolt’s BDC-1001 for the treatment of patients with HER2-expressed solid tumors. The program encompasses formulation devel...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters